Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00991965
Other study ID # P09-03
Secondary ID
Status Terminated
Phase N/A
First received October 6, 2009
Last updated February 15, 2012
Start date October 2009
Est. completion date November 2010

Study information

Verified date October 2011
Source Medtronic Spinal and Biologics
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this research study is to shorten the treatment time course for patients who are scheduled for surgery to have a dental implant(s) placed into the upper front part of their mouths and need to have more bone in their jaws to support the implant.


Description:

The INFUSE® Bone Graft is a device approved by the FDA to be used instead of using your own bone (from another site on your body) to replace missing bone in your jaw. INFUSE® Bone Graft is commercially available and is made up of 2 parts - recombinant human Bone Morphogenetic Protein-2 (rhBMP 2) placed on an absorbable collagen sponge (ACS). The rhBMP-2 is a genetically altered protein which recruits bone-forming cells to the surgical area and changes local cells to bone. ACS is made from Type I collagen from bovine (cattle) tendon. It helps to hold the rhBMP-2 in place and acts as a support for the growing bone. The sponge itself will reabsorb in time as the new bone forms.

The purpose of this research study is to shorten the treatment time course for the patients. This post-market study has been designed to further evaluate the effectiveness and safety of INFUSE® Bone Graft, along with dental implant placement, in a single procedure.


Recruitment information / eligibility

Status Terminated
Enrollment 8
Est. completion date November 2010
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Able to provide written informed consent

2. =18 years

3. Scheduled for dental implant into maxillary alveolar ridge

4. Negative urine pregnancy test for patients of child bearing potential and agreement not become pregnant for at least 12 months after surgery

5. Is able to comply with all study-related procedures, including exercising good oral hygiene

6. A prosthodontic treatment plan has been drafted.

Exclusion Criteria:

1. Known hypersensitivity to rhBMP-2, bovine Type I collagen or other components of the formulation

2. Known hypersensitivity to titanium

3. Operative site is in the area of a resected or extant tumor

4. Any active malignancy or current treatment for a malignancy

5. Active infection at operative site

6. History of prior exposure to rhBMP-2/ACS

7. Received and failed a previous alveolar ridge augmentation procedure

8. Pathology that would either compromise a bone grafting procedure, or interfere with obtaining quantitative measurements from postoperative CT scans

9. Significant untreated periodontal disease (> Grade III), caries, or chronic inflammation of the oral cavity at operative site

10. Active use of any nicotine-containing products such as, but not limited to, smoking and chewing tobacco, nicotine patch, nicotine gum, etc.

11. Insulin-dependent diabetic, or has known HgbA1c levels >6.5 %

12. History of malignancy within the past 5 years except for basal cell or squamous cell carcinoma of the skin

13. Patients who are lactating

14. History of metabolic bone disease, excluding idiopathic osteoporosis

15. History of autoimmune disease (e.g., documented multiple allergies, systemic lupus erythematosus, dermatomyositis, etc.) or immunosuppressive disease (e.g., Human Immunodeficiency Virus or Acquired Immune Deficiency Syndrome)

16. History of immune deficiency due to other treatments (e.g., radiation therapy, chemotherapy, steroid therapy)

17. History of adverse reaction to prior exposure to silicone or injectable collagen

18. Treatment with an investigational therapy within 1 month before the surgical procedure or plans to be treated with an investigational therapy during the study period.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Device:
INFUSE® Bone Graft
Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Medtronic Spinal and Biologics Averion International Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Stability and osseointegration of endosseous dental implants 6 months post-implantation No
Secondary Evaluate evidence of successful initial INFUSE® Bone Graft and dental implant placement. Assess percent bone fill within the defect and safety of INFUSE®. Outcomes will be assessed via CT scans and periapical X-rays. 6 months post-implantation Yes
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05470673 - Autogenous Demineralized Dentin Graft Combined With Injectable PRF + Metronidazole Versus Autogenous Demineralized Dentin Graft Alone for Alveolar Ridge Preservation N/A
Recruiting NCT02580721 - The Influence of Mucosal Tissue Thickness on Soft and Hard Tissue Changes Around Implants N/A
Completed NCT02515058 - Ridge Preservation Following Tooth Extraction Using Two Mineralized Cancellous Bone Allografts N/A
Enrolling by invitation NCT02209311 - Effectiveness and Safety of Method of Maxilla Alveolar Process Reconstruction Using Synthetic Tricalcium Phosphate and Autologous MMSCs Phase 1/Phase 2
Completed NCT02602223 - Comparison of Amnion Chorion Membrane vs. Dense Polytetrafluoroethylene Membrane in Ridge Preservation Procedures Phase 2
Completed NCT02255149 - A Feasibility Study for Growth Bone Vertically With Titanium Mesh and Allograft in Lower Posterior Jaw N/A
Recruiting NCT05674331 - Clinical, Radiographical, Histological Evaluation and Blood Flow Analysis of Alveolar Ridge Preservation N/A
Recruiting NCT06081296 - Dimensional Changes in Alveolar Ridge Preservation N/A
Completed NCT03944811 - Bone Height Gain Following Transcrestal Sinus Floor Elevation Using Piezoelectric Surgery Versus The Conventional Osteotome Technique N/A
Completed NCT03045458 - Associations of Alveolar Bone Loss and Interleukin-1β Levels in One and Two Stage Surgical Procedures N/A
Completed NCT05595746 - Radiological Bone Loss on Different Levels of Dental Implants N/A
Completed NCT03357705 - Effectiveness in Limiting the Need to Elevate the Maxillary Sinus N/A
Recruiting NCT05311735 - Mineralized and Partial Demineralized Dentin Graft Compared to FDBA N/A
Completed NCT05494476 - Stability of the Marginal Bone Around Subcrestal Implants N/A
Not yet recruiting NCT05536479 - Evaluation of Autogenous Stored Versus Autogenous Fresh Mineralized Dentin Graft for Alveolar Ridge Preservation N/A
Active, not recruiting NCT02275767 - Histological Evaluation of Healing Following Ridge Preservation Using a Combined Cortical/Cancellous Mineralized Freeze-Dried Bone Allograft N/A
Active, not recruiting NCT02120053 - Interest of Bone Substitute Material in Immediate Complete Denture Phase 2/Phase 3
Completed NCT01728844 - GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery N/A
Terminated NCT00991432 - Localized Alveolar Ridge Augmentation With Space Maintenance Devices N/A
Completed NCT03149172 - Comparison of Post Tooth Extraction Healing Using Different Xenograft Materials N/A